{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T10:50:30Z","timestamp":1789815030009,"version":"4.0.1"},"reference-count":74,"publisher":"Public Library of Science (PLoS)","issue":"11","license":[{"start":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T00:00:00Z","timestamp":1447804800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0143013","type":"journal-article","created":{"date-parts":[[2015,11,18]],"date-time":"2015-11-18T18:54:40Z","timestamp":1447872880000},"page":"e0143013","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":67,"title":["Assessment of Interactions between Cisplatin and Two Histone Deacetylase Inhibitors in MCF7, T47D and MDA-MB-231 Human Breast Cancer Cell Lines \u2013 An Isobolographic Analysis"],"prefix":"10.1371","volume":"10","author":[{"given":"Anna","family":"Wawruszak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jarogniew J.","family":"Luszczki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aneta","family":"Grabarska","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ewelina","family":"Gumbarewicz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Magdalena","family":"Dmoszynska-Graniczka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof","family":"Polberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrzej","family":"Stepulak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2015,11,18]]},"reference":[{"key":"ref1","unstructured":"GLOBOCAN 2012: Estimated Cancer Incidence, Mortality and Prevalence Worldwide in 2012. Available: <ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx\" xlink:type=\"simple\">http:\/\/globocan.iarc.fr\/Pages\/fact_sheets_cancer.aspx<\/ext-link>."},{"key":"ref2","doi-asserted-by":"crossref","first-page":"983","DOI":"10.1517\/14656566.2015.1032246","article-title":"Therapies for triple negative breast cancer","volume":"16","author":"E Andreopoulou","year":"2015","journal-title":"Expert Opin Pharmacother"},{"key":"ref3","doi-asserted-by":"crossref","first-page":"4891","DOI":"10.1200\/JCO.2007.14.1168","article-title":"Trends in survival over the past two decades among white and black patients with newly diagnosed stage IV breast cancer","volume":"26","author":"S Dawood","year":"2008","journal-title":"J Clin Oncol"},{"key":"ref4","doi-asserted-by":"crossref","first-page":"1902","DOI":"10.1200\/JCO.2014.57.6660","article-title":"TBCRC009: A Multicenter Phase II Clinical Trial of Platinum Monotherapy With Biomarker Assessment in Metastatic Triple-Negative Breast Cancer","volume":"33","author":"SJ Isakoff","year":"2015","journal-title":"J Clin Oncol"},{"issue":"11","key":"ref5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0112880","article-title":"Decitabine Rescues Cisplatin Resistance in Head and Neck Squamous Cell Carcinoma","volume":"9","author":"C Viet","year":"2014","journal-title":"PLoS One"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"11641","DOI":"10.18632\/oncotarget.2604","article-title":"Cisplatin in combination with Phenethyl Isothiocyanate (PEITC), a potential new therapeutic strategy for malignant pleural mesothelioma","volume":"5","author":"I Denis","year":"2014","journal-title":"Oncotarget"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1247","DOI":"10.1634\/theoncologist.12-10-1247","article-title":"FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma","volume":"12","author":"B Mann","year":"2007","journal-title":"Oncologist"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1080\/10428190701817258","article-title":"Phase I trial of oral vorinostat (suberoylanilide hydroxamic acid, SAHA) in patients with advanced multiple myeloma","volume":"49","author":"P Richardson","year":"2008","journal-title":"Leuk Lymphoma"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1182\/blood-2007-06-098061","article-title":"Phase 1 study of the histone deacetylase inhibitor vorinostat (suberoylanilide hydroxamic acid [SAHA]) in patients with advanced leukemias and myelodysplastic syndromes","volume":"111","author":"G Garcia-Manero","year":"2008","journal-title":"Blood"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1200\/JCO.2008.19.0694","article-title":"Phase II trial of vorinostat in recurrent glioblastoma multiforme: a north central cancer treatment group study","volume":"27","author":"E Galanis","year":"2009","journal-title":"J Clin Oncol"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1007\/s10637-008-9131-6","article-title":"Early phase II trial of oral vorinostat in relapsed or refractory breast, colorectal, or non-small cell lung cancer","volume":"26","author":"J Vansteenkiste","year":"2006","journal-title":"Invest New Drugs"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: a Gynecologic Oncology Group study","volume":"109","author":"S Modesitt","year":"2008","journal-title":"Gynecol Oncol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1002\/med.10017","article-title":"Anti-tumor mechanisms of valproate: a novel role for an old drug","volume":"22","author":"R Blaheta","year":"2002","journal-title":"Med Res Rev"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"469","DOI":"10.4103\/0973-1482.137937","article-title":"Epigenetic therapy of cancer with histone deacetylase inhibitors","volume":"10","author":"K Lakshmaiah","year":"2014","journal-title":"J Cancer Res Ther"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"5541","DOI":"10.1038\/sj.onc.1210620","article-title":"Histone deacetylase inhibitors: molecular mechanisms of action","volume":"26","author":"W Xu","year":"2007","journal-title":"Oncogene"},{"key":"ref16","doi-asserted-by":"crossref","first-page":"9","DOI":"10.4137\/GEG.S12270","article-title":"Use of Epigenetic Drugs in Disease: An Overview","volume":"6","author":"S Heerboth","year":"2014","journal-title":"Genet Epigenet"},{"key":"ref17","first-page":"229","article-title":"Discovery of PAT-1102, a Novel, Potent and Orally Active Histone Deacetylase Inhibitor with Antitumor Activity in Cancer Mouse Models","volume":"35","author":"J Hiriyan","year":"2014","journal-title":"Anticancer Res"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"4595","DOI":"10.1007\/s11033-014-3330-3","article-title":"Valproic acid inhibits the proliferation of SHSY5Y neuroblastoma cancer cells by downregulating URG4\/URGCP and CCND1 gene expression","volume":"41","author":"Y Dodurga","year":"2014","journal-title":"Mol Biol Rep"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"180363","DOI":"10.1155\/2012\/180363","article-title":"Mechanism of growth inhibition of prostate cancer xenografts by valproic acid","volume":"2012","author":"A Sidana","year":"2012","journal-title":"J Biomed Biotechnol"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.biocel.2008.08.019","article-title":"Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status","volume":"41","author":"L Travaglini","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"issue":"11","key":"ref21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080657","article-title":"Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model","volume":"8","author":"D Feng","year":"2013","journal-title":"PLoS One"},{"key":"ref22","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hed.21734","article-title":"Valproic acid: growth inhibition of head and neck cancer by induction of terminal differentiation and senescence","volume":"34","author":"CP Gan","year":"2012","journal-title":"Head Neck"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"854","DOI":"10.1002\/jcb.24422","article-title":"Sodium valproate potentiates staurosporine-induced apoptosis in neuroblastoma cells via Akt\/survivin independently of HDAC inhibition","volume":"114","author":"RD Shah","year":"2013","journal-title":"J Cell Biochem"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"203","DOI":"10.3892\/ol.2013.1666","article-title":"Histone deacetylase inhibitor, valproic acid, radiosensitizes the C6 glioma cell line in vitro","volume":"7","author":"Y Zhou","year":"2014","journal-title":"Oncol Lett"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11255-013-0609-6","article-title":"Role of SMAD4 in the mechanism of valproic acid&apos;s inhibitory effect on prostate cancer cell invasiveness","volume":"46","author":"W Jiang","year":"2014","journal-title":"Int Urol Nephrol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"996","DOI":"10.7150\/jca.12135","article-title":"The Histone Deacetylase Inhibitor Vaproic Acid Induces Cell Growth Arrest in Hepatocellular Carcinoma Cells via Suppressing Notch Signaling","volume":"6","author":"G Sun","year":"2015","journal-title":"J Cancer"},{"key":"ref27","first-page":"8291","article-title":"Induction of apoptosis and autophagy in metastatic thyroid cancer cells by valproic acid (VPA)","volume":"8","author":"Y Xu","year":"2015","journal-title":"Int J Clin Exp Pathol"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"77","DOI":"10.4238\/2012.January.13.1","article-title":"Sodium valproate inhibits MDA-MB-231 breast cancer cell migration by upregulating NM23H1 expression","volume":"11","author":"GF Li","year":"2012","journal-title":"Genet Mol Res"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1007\/s11010-011-1085-x","article-title":"VPA inhibits breast cancer cell migration by specifically targeting HDAC2 and down-regulating Survivin","volume":"361","author":"L Zhang","year":"2012","journal-title":"Mol Cell Biochem"},{"key":"ref30","first-page":"700","article-title":"The correlation between telomerase activity and Bax\/Bcl-2 ratio in valproic acid-treated MCF-7 breast cancer cell line","volume":"18","author":"Z Vafaiyan","year":"2015","journal-title":"Iran J Basic Med Sci"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.biocel.2008.08.019","article-title":"Epigenetic reprogramming of breast cancer cells by valproic acid occurs regardless of estrogen receptor status","volume":"41","author":"L Travaglini","year":"2009","journal-title":"Int J Biochem Cell Biol"},{"issue":"11","key":"ref32","article-title":"The anti-tumor effects and molecular mechanisms of suberoylanilide hydroxamic acid (SAHA) on the aggressive phenotypes of ovarian carcinoma cells","volume":"8","author":"S Chen","year":"2013","journal-title":"PLoS One"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/dote.12127","article-title":"Anticancer effects of suberoylanilide hydroxamic acid in esophageal squamous cancer cells in vitro and in vivo","volume":"27","author":"C Tzao","year":"2014","journal-title":"Dis Esophagus"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1021\/mp3004622","article-title":"Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2\/M cycle arrest","volume":"10","author":"S Vijayaraghavalu 1","year":"2013","journal-title":"Mol Pharm"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.4161\/auto.25664","article-title":"Suberoylanilide hydroxamic acid (SAHA) causes tumor growth slowdown and triggers autophagy in glioblastoma stem cells","volume":"9","author":"MT Chiao","year":"2013","journal-title":"Autophagy"},{"key":"ref36","doi-asserted-by":"crossref","first-page":"881","DOI":"10.7150\/ijms.5011","article-title":"Molecular mechanism of SAHA on regulation of autophagic cell death in tamoxifen-resistant MCF-7 breast cancer cells","volume":"9","author":"YJ Lee","year":"2012","journal-title":"Int J Med Sci"},{"key":"ref37","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/1423-0127-17-76","article-title":"Suberoylanilide hydroxamic acid induces apoptosis and sub-G1 arrest of 320 HSR colon cancer cells","volume":"17","author":"PC Sun","year":"2010","journal-title":"J Biomed Sci"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/bjc.2014.547","article-title":"Histone deacetylase inhibitor SAHA epigenetically regulates miR-17-92 cluster and MCM7 to upregulate MICA expression in hepatoma","volume":"112","author":"H Yang","year":"2015","journal-title":"Br J Cancer"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects","volume":"3","author":"A Florea","year":"2011","journal-title":"Cancers"},{"key":"ref40","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/S0031-6997(25)06847-4","article-title":"The search for synergy: a critical review from a response surface perspective","volume":"47","author":"WR Greco","year":"1995","journal-title":"Pharmacol Rev"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"J Litchfield","year":"1949","journal-title":"J Pharmacol Exp Ther"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s00210-007-0144-z","article-title":"Isobolographic analysis of interaction between drugs with nonparallel dose-response relationship curves: a practical application","volume":"375","author":"JJ Luszczki","year":"2007","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1007\/s00210-004-0867-z","article-title":"Isobolographic profile of interactions between tiagabine and gabapentin: a preclinical study","volume":"369","author":"JJ Luszczki","year":"2004","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1007\/s00210-006-0100-3","article-title":"Biphasic characteristic of interactions between stiripentol and carbamazepine in the mouse maximal electroshock-induced seizure model: a three-dimensional isobolographic analysis","volume":"374","author":"JJ Luszczki","year":"2006","journal-title":"Naunyn-Schmiedebergs Arch Pharmacol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1124\/jpet.104.067264","article-title":"Isobolographic analysis for combinations of a full and partial agonist: curved isoboles","volume":"310","author":"Y Grabovsky","year":"2004","journal-title":"J Pharmacol Exp Ther"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1124\/jpet.106.104117","article-title":"An overview of drug combination analysis with isobolograms","volume":"319","author":"RJ Tallarida","year":"2006","journal-title":"J Pharmacol Exp Ther"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.pharmthera.2006.08.002","article-title":"Interactions between drugs and occupied receptors","volume":"113","author":"RJ Tallarida","year":"2007","journal-title":"Pharmacol Ther"},{"key":"ref48","doi-asserted-by":"crossref","DOI":"10.1201\/9781420036107","article-title":"Drug synergism and dose-effect data analysis","author":"RJ Tallarida","year":"2000"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1007\/s00280-008-0747-1","article-title":"Valproic acid as a therapeutic agent for head and neck squamous cell carcinomas","volume":"63","author":"R Erlich","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1016\/j.bcp.2007.03.009","article-title":"Enhancement of cisplatin induced apoptosis by suberoylanilide hydroxamic acid in human oral squamous cell carcinoma cell lines","volume":"73","author":"J Shena","year":"2007","journal-title":"Biochem Pharmacol"},{"key":"ref51","article-title":"Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug","author":"A Eastman","year":"2009"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1007\/s00280-009-0969-x","article-title":"Enhancement of cisplatin cytotoxicity by SAHA involves endoplasmic reticulum stress-mediated apoptosis in oral squamous cell carcinoma cells","volume":"64","author":"M Suzuki","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref53","first-page":"7291","article-title":"Inhibition of histone deacetylase increases cytotoxicity to anticancer drugs targeting DNA","volume":"63","author":"MS Kim","year":"2003","journal-title":"Cancer Res"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1016\/S0031-6997(25)00026-2","article-title":"What is synergy?","volume":"41","author":"MC Berenbaum","year":"1989","journal-title":"Pharmacol Rev"},{"key":"ref55","article-title":"Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry","author":"J Prater","year":"2015","journal-title":"J Cancer Res Clin Oncol"},{"issue":"11","key":"ref56","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080657","article-title":"Targeting of histone deacetylases to reactivate tumour suppressor genes and its therapeutic potential in a human cervical cancer xenograft model","volume":"8","author":"D Feng","year":"2013","journal-title":"PLoS One"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.taap.2011.08.018","article-title":"Enhanced suppression of tumor growth by concomitant treatment of human lung cancer cells with suberoylanilide hydroxamic acid and arsenic trioxide","volume":"257","author":"CW Chien","year":"2011","journal-title":"Toxicol Appl Pharmacol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"J Lee","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1349-7006.2008.00793.x","article-title":"Valproic acid resensitizes cisplatin-resistant ovarian cancer cells","volume":"99","author":"C Lin","year":"2008","journal-title":"Cancer Sci"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.tips.2014.08.001","article-title":"Drugging the HDAC6-HSP90 interplay in malignant cells","volume":"35","author":"OH Kr\u00e4mer","year":"2014","journal-title":"Trends Pharmacol Sci"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1007\/s00280-010-1324-y","article-title":"Identyfication of type-specific anticancer histone deacetylase inhibitors: road to success","volume":"66","author":"N Nighat","year":"2010","journal-title":"Cancer Chemother Pharmacol"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.canlet.2009.02.027","article-title":"Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer","volume":"280","author":"O Bortugno","year":"2009","journal-title":"Cancer Lett"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.canlet.2007.10.006","article-title":"Valproic acid is a selective antiproliferative agent in estrogen-sensitive breast cancer cells","volume":"259","author":"N Fortunati","year":"2008","journal-title":"Cancer Letters"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.febslet.2004.06.018","article-title":"Histone deacetylase inhibitors regulate p21WAF1 gene expression at the posttranscriptional level in HepG2 cells","volume":"570","author":"C Hirsch","year":"2004","journal-title":"FEBS Lett"},{"key":"ref65","first-page":"3044","article-title":"Comparitive effects of histone deaceylase inhibitors on p53 target gene expression, cell cycle and apoptosis in MCF-7 breast cancer cells","volume":"112","author":"A Knutson","year":"2010","journal-title":"Oncol. Rep"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1016\/j.biochi.2009.03.017","article-title":"Unusual DNA binding modes for metal anticancer complexes","volume":"91","author":"A Pizarro","year":"2009","journal-title":"Biochemie"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"327","DOI":"10.1158\/1535-7163.327.3.3","article-title":"Down-regulation of Bcl-2 is associated with cisplatin resistance in human small cell lung cancer H69 cells","volume":"3","author":"S Biswas","year":"2004","journal-title":"Mol Cancer Ther"},{"key":"ref68","article-title":"Cisplatin: Chemistry and Biochemistry of a Leading Anticancer Drug","author":"A Eastman","year":"2009"},{"key":"ref69","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.3390\/cancers3011351","article-title":"Cisplatin as an Anti-Tumor Drug: Cellular Mechanisms of Activity, Drug Resistance and Induced Side Effects","volume":"3","author":"A Florea","year":"2011","journal-title":"Cancers"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"14639","DOI":"10.1073\/pnas.1008522107","article-title":"Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair","volume":"107","author":"J Lee","year":"2010","journal-title":"Proc Natl Acad Sci U S A"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"1218","DOI":"10.1111\/j.1349-7006.2008.00793.x","article-title":"Valproic acid resensitizes cisplatin-resistant ovarian cancer cells","volume":"99","author":"C Lin","year":"2008","journal-title":"Cancer Sci"},{"key":"ref72","doi-asserted-by":"crossref","first-page":"1699","DOI":"10.1038\/sj.bjc.6603777","article-title":"Valproic acid inhibits adhesion of vincristine- and cisplatin-resistant neuroblastoma tumour cells to endothelium","volume":"96","author":"R Blaheta","year":"2007","journal-title":"Br J Cancer"},{"key":"ref73","doi-asserted-by":"crossref","first-page":"3923","DOI":"10.1200\/JCO.2005.14.167","article-title":"Phase I study of an oral histone deacetylase inhibitor, suberoylanilide hydroxamic acid, in patients with advanced cancer","volume":"23","author":"WK Kelly","year":"2005","journal-title":"J Clin Oncol"},{"key":"ref74","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1210\/jc.2004-1355","article-title":"Valproic acid induces apoptosis and cell cycle arrest in poorly differentiated thyroid cancer cells","volume":"90","author":"MG Catalano","year":"2005","journal-title":"J Clin Endocrinol Metab"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0143013","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,5,31]],"date-time":"2025-05-31T12:49:51Z","timestamp":1748695791000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0143013"}},"subtitle":[],"editor":[{"given":"Eric","family":"Asselin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2015,11,18]]},"references-count":74,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2015,11,18]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0143013","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015,11,18]]}}}